Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma Reply

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandala, Georgina V. Long, Victoria G. Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J.M. van den EertweghJean Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C. Lorigan, Alexander C.J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)944-946
Number of pages3
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume39
Issue number8
DOIs
Publication statusPublished - 10 Mar 2021

Keywords

  • Adjuvant therapy
  • Clinical trials
  • Hormonal therapy
  • Metastatic relapse
  • Risk of relapse
  • Stage at diagnosis
  • Staging systems
  • pembrolizumab

Cite this